Covalon’s medical product adopted by U.S. pediatric hospital’s program
by CM Staff
The trial involved the use of SurgiClear post-operatively on a total of 600 patients ranging in age from 2 months to 66 years that had congenital heart surgery.
MISSISSAUGA — Covalon Technologies Ltd., an advanced medical technologies company, announces that SurgiClear, a dual antimicrobial postoperative dressing, is now part of the surgical site infection prevention bundle used by Texas Children’s Hospital Heart Unit after the dressing successfully eliminated surgical site infections.
“To see SurgiClear in the hands of the top pediatric cardiac surgery teams and making a difference in the lives of children and their parents, is exactly what drives innovation here at Covalon,” says Brian Pedlar, CEO of Covalon. “We designed SurgiClear to outperform other post-operative wound care dressings, with the critical goal being to prevent post-operative complications from jeopardizing the success of life-saving procedures.”
As part of a quality improvement project, the Heart Unit at Texas Children’s Hospital ran a trial to strengthen post operative wound care and infection prevention practices by trialing Covalon’s SurgiClear product. During the course of the one-year trial, infection rates steadily declined and outcomes for patients improved. The trial involved the use of SurgiClear post-operatively on a total of 600 patients ranging in age from 2 months to 66 years that had congenital heart surgery.
“Parents of our pediatric heart surgery patients are often concerned and worried about their child’s upcoming surgery,” said Sophia C. Bailey, MSN, BSN, RN, CNOR, of Texas Children’s Hospital in Houston, Texas. “However, surgery is only one critical element of the post-operative journey. Healing and prevention of surgical site infection are paramount for patient outcomes. Since we began using SurgiClear, we have had excellent results maintaining the immediate perimeter of our incisions. This initiative has improved healing and prevention of wound contamination and infection, resulting in much-needed peace of mind for both parents and clinicians.”
Since the completion of the trial, the product has been used as a first-line wound dressing on all patients over two months of age being treated by the Congenital Heart Surgery Service at Texas Children’s.